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Objective: In our study, the bioavailability and tolerability of the proposed generic formulation with the
established reference formulation of repaglinide 2 mg were compared in a fasting, healthy Chinese male
population.
Methods: This 2-week, open-label, randomized-sequence, single-dose, 2-period crossover study was
conducted in 22 healthy native Han Chinese male volunteers. Eligible subjects were randomly assigned
in a 1:1 ratio to receive a single 2-mg dose of the test or reference formulation, followed by a 7-day
washout period and administration of the alternate formulation. After an overnight fast, subjects
received a single oral dose of repaglinide (2 mg). Blood samples were drawn at predetermined time
points (0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, and 6.0 hours). All plasma concentrations of
repaglinide were measured by LC-MS/MS. The observed Cmax, Tmax, t1/2, and AUC were assessed. The
formulations were to be considered bioequivalent if the ln-transformed ratios of Cmax and AUC were
within the predetermined bioequivalence range of 80% to 125% established by the State Food and Drug
Administration of the People’s Republic of China. Tolerability was assessed throughout the study via
subject interview, vital signs, and blood sampling.
Results: The mean (SD) age of the subjects was 24.2 (2.3) years; their mean (SD) weight was 62.6 (5.8) kg,
their mean (SD) height was 172 (5.7) cm, and their mean (SD) body mass index was 21.0 (1.1). The mean
(SD) Cmax for repaglinide with the test and reference formulations were 20.0 (5.1) and 18.7 (8.7) ng/mL.
The AUC0–t for the test formulation was 46.3 (15.1) and AUC0–1 was 47.9 (16.5) ngh/mL. With the
reference formulation, the corresponding values were 46.4 (26.1) and 49.0 (31.3) ngh/mL. The mean
(SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the
mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively. The ln-transformed ratios
of Cmax, AUC0–t, and AUC0–1 were 113.6:1, 105.6:1, and 104.7:1. The corresponding 90% CIs were 99.8 to
129.2, 93.4 to 119.5, and 91.8 to 119.5, respectively.
Conclusions: This single-dose study found that the test and reference formulations of repaglinide met the
regulatory criteria for bioequivalence in these fasting, healthy Chinese male volunteers. Both formula-
tions appeared to be well tolerated. ClinicalTrials.gov identiﬁer: 2012L01684.
Crown Copyright & 2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license.evier Inc.
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Repaglinide is a prandial glucose regulator for the treatment
of type 2 diabetes mellitus. As a short-acting insulin secretagogue,
it reduces blood glucose concentrations by enhancing glucose-
stimulated insulin release in pancreatic β-cells.1,2 Available clinical
data indicate that repaglinide, given 2 to 4 times daily before
each main meal, is an effective agent in the management of type
2 (noninsulin-dependent) diabetes mellitus. During short- andD license.
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few patients have withdrawn from treatment because of adverse
effects.3,4
The pharmacokinetic proﬁle of repaglinide has been reported
in humans.5–7 Cmax is reached 30 to 60 minutes after adminis-
tration. After reaching Cmax, plasma levels decrease rapidly and the
drug is eliminated within 4 to 6 hours. Its absolute bioavailability
is 63%, and its absorption is not affected by food. In humans, it
is highly bound (498%) to plasma protein albumin. It is rapidly
absorbed after oral administration with a bioavailability 60%.
During elimination, repaglinide is ﬁrst taken up from the blood to
hepatocytes by human organic anion-transporting polypeptides
1B1 (OATP1B1) expressed on the basolateral membrane of hep-
atocytes and then transformed into inactive metabolites via
cytochrome P-450 (CYP) 2C8 and CYP3A4 in the liver, which are
genetically polymorphic enzymes.8–11
Despite repaglinide having been in widespread clinical use for
many years, there is little information on its pharmacokinetics in
the Chinese population.12 A search of the literature for reports on
the pharmacokinetics of repaglinide identiﬁed a small number of
published pharmacokinetic studies in white patients.5–7 Few
reports were identiﬁed concerning the pharmacokinetic properties
of repaglinide in a Chinese population.12
Before allowing the marketing of generic repaglinide, the State
Food and Drug Administration (SFDA) of China requires pharma-
cokinetic studies of the bioequivalence of generic and branded
formulations. Therefore, the purpose of our single-dose study was
to compare the bioavailability and tolerability of the proposed
generic formulation with the established reference formulation of
repaglinide in a fasting, healthy Chinese male population.Study Population and Methods
Trial design
This single-center, randomized, open-label, 2-phase study was
designed and conducted at Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, People’s
Republic of China. The study was conducted according to the
principles of the Declaration of Helsinki and its amendments for
biomedical research involving human subjects and the principles
of the Good Clinical Practice Guidelines. The clinical trial was
approved by the SFDA (approval No. 2012L01684), and the clinical
protocol and the informed consent form were approved by the
local ethics committee at Tongji Medical College, Huazhong Uni-
versity of Science and Technology (approval No. [2012]162). All
eligible participants were informed of the aim and risks of the
study by the clinical investigators and provided written informed
consent before participation.
Subjects were hospitalized at 10 PM the night before the
beginning of the study. They were randomly assigned, in a 1:1
ratio using a computer-generated table of random numbers, to
receive a single 2-mg dose of the test formulation or the reference
formulation of repaglinide under fasting condition during Period
1 and the alternate formulation during Period 2. The 2 periods of
administration were separated by a 7-day washout period. The test
formulation of repaglinide (1 mg; lot No. 120801) was provided by
Sichuan Deren Pharmaceutical Co, Ltd (Sichuan, China). The
reference formulation of repaglinide (1 mg; lot No. AM70752)
was provided by Beijing Novo Nordisk Pharma Co Ltd (Beijing,
China).
During each period, before administration of the drug, an
indwelling venous catheter (Becton Dickinson Medical Devices
Co, Ltd, Suzhou, People’s Republic of China) was placed in a
suitable forearm vein, and a 5-mL blood sample was drawn intoa vacuum tube with heparin sodium (Tianjin Biochemical Pharma-
ceutical Factory Co, Ltd, Tianjin, People’s Republic of China). Then,
according to the US Food and Drug Administration guidelines on
repaglinide, the patients were administered, under the supervision
of study investigators, 2 repaglinide tablets orally with 250 mL 20%
v/v glucose solution. Sixty milliliters of 20% v/v glucose solution
were administered every 15 minutes until 4 hours after admin-
istration. Intake of food was not permitted after drug administra-
tion; a standardized lunch (200 g cooked rice, 200 g vegetables, 50
g pork, and 50 mL tomato soup) was provided at 4 hours after
administration.
Additional blood samples were drawn at 0.25, 0.5, 0.75, 1, 1.25,
1.5, 2.0, 2.5, 3.0, 4.0, 5.0, and 6.0 hours after administration. Plasma
was obtained by centrifugation at 1000 g for 10 minutes at 51C
(LDZ5-2 Auto-balance Table Centrifuge, Beijing Medical Centri-
fuges Ltd, Beijing, People’s Republic of China) and stored at 801C
until analyzed using an LC-MS/MS method.
Intense physical activity, smoking, and consumption of beverages
containing xanthine derivatives or alcohol were not allowed during
the course of the study. Subjects were under continuous medical
supervision at the study site throughout the 2-week study period.
Inclusion and exclusion criteria
Healthy, nonsmoking, male Han Chinese volunteers aged 18
to 40 years with body mass index 19 to 24 were enrolled in the
study. Before study entry, subjects were interviewed (regarding
their occupation, smoking and drinking habits, and medical
history) and underwent a routine physical examination, including
vital sign monitoring (ie, blood pressure, heart rate, respiratory
rate, and temperature), ECG, chest radiograph, and laboratory
analysis (ie, hematology, blood biochemistry, hepatic and renal
function, and urinalysis) to ensure that they were healthy enough
to participate in the study.
Subjects were excluded if they had a history or evidence of a
renal, gastrointestinal, hepatic, or hematologic abnormality; any
acute or chronic disease; or an allergy to any chemicals. Subjects
who had used drugs of any kind within the 2 weeks before the
start of or during the study were excluded, as were those who
consumed a moderate amount of alcohol daily (ie, 41 L beer or its
equivalent [ie, 50 g/day alcohol]).
Determination of plasma concentrations
The analysis of the concentrations of repaglinide in plasma was
conducted at Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, People’s Republic
of China, after the completion of both periods. The concentration of
repaglinide in plasma was measured using a validated LC-MS/MS
method. The LC-MS/MS system was a Shimadzu LC-30AD pump
(Shimadzu, Kyoto, Japan) and a SIL-30AC autosampler (Shimadzu,
Kyoto, Japan) coupled to an API QTRAP 5500 triple quadrupole
mass spectrometer with an electrospray ionization source (AB
Sciex, Concord, Ontario, Canada). The tandem mass spectrometer
was operated under multiple reaction monitoring (MRM) using an
electrospray atmospheric pressure ionization source in positive ion
mode. The optimized condition consisted of a collision-activated
dissociation gas of the medium, a curtain gas of 25 psi, a nebulizer
gas of 50 psi, a TurboIonSpray gas of 50 psi, an ionspray voltage of
þ5500 V, a source temperature of 5501C, and an entrance
potential of þ10 V for repaglinide and the internal standard
(nateglinide). Quantiﬁcation was operated in MRM of the transi-
tions m/z 453.1-m/z 230.2 for repaglinide, and m/z 318.0-m/z
166.1 for nateglinide. MRM data were acquired and the chromato-
grams were integrated with Analyst 1.6.1 software (AB Sciex,
Concord, Ontario, Canada).
Table I
Mean [SD] pharmacokinetic parameters of repaglinide after single-dose adminis-
tration of 2 2-mg tablet formulations of repaglinide in 22 healthy Chinese male
volunteers.
Parameter Reference (n ¼ 22) Test (n ¼ 22)
Mean (SD)
Cmax, ng/mL 18.7 (8.7) 20.0 (5.1)
Tmax, h 1.5 (0.8) 1.2 (0.7)
t1/2, h 0.9 (0.3) 1.0 (0.3)
AUC0–t, ng h/mL 46.4 (26.1) 46.3 (15.1)
AUC0–1, ng h/mL 49.0 (31.3) 47.9 (16.5)
AUC0–t/AUC0–1 0.963 (0.04) 0.971 (0.02)
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2100 ng/mL in mobile phase) and 20 μL 50% v/v menthol-water
were added to a 200 μL plasma sample in a screw-cap glass tube.
After vortex mixing for 20 seconds, 600 μL acetonitrile was added
to the mixture to precipitate protein and the sample was vortex
mixed for 60 seconds and centrifuged at 13,000 rpm at 41C for
10 minutes; 150 μL of the upper layer was transferred to an
injection bottle that was loaded into an autosampler cabinet and
5 μL aliquot was injected into the LC-MS/MS system.
Chromatographic separation was performed on a Ultimate C18
column (150 mm  2.1 mm, 5 mm; Welch Materials, Potomac,
Md). The mobile phase consisted of acetonitrile: 0.1% aqueous
acetic acid (70:30 v/v) at an isocratic ﬂow rate of 0.3 mL/minute,
and the injection volume was 5 mL and the run time was
4.5 minutes. The temperatures of the analytical column and
autosampler were set at 401C and 41C, respectively. Under these
conditions, the retention time for repaglinide and nateglinide were
3.72 minutes and 2.75 minutes, respectively.
Tolerability assessment
Tolerability was assessed using monitoring of vital signs
(ie, blood pressure, body temperature, heart rate, and respiratory
rate), physical examination, ECG, and routine blood and urine
tests, along with blood biochemical tests (ie, hepatic and renal
function), at the start as well as at the end of the study. Blood
pressure was measured using a standard mercury sphygmoman-
ometer on the left arm after 5 minutes’ rest, in the sitting position.
In addition, vital signs were assessed at 0, 0.5, 1, 3, and 6 hours
after drug administration. Adverse events were evaluated by the
study physicians for intensity, seriousness, and relationship to the
study medication. Adverse events were deﬁned as mild (awareness
of a sign or symptom but easily tolerated), moderate (discomfort
sufﬁcient to cause interference with normal activities), or severe
(incapacitating, with an inability to perform normal activities).
Causality between the study drug and an adverse event were
described by the study physicians as “certainly,” “probably,”
“possibly,” “suspected,” or “not related.”
Pharmacokinetic and statistical analyses
Using a power analysis (expected value, Z1-β ¼ 0.8), it was
determined that the power of the ANOVA was 40.8 at a 90% CI
according to the US Food and Drug Administration guidelines on
bioequivalence testing,13 indicating that 22 subjects would be
sufﬁcient for the purposes of our study.
The different parameters (Cmax, AUC0–t, AUC0–1, Tmax, and t1/2)
of an oral repaglinide tablet given under fasting condition were
tested with an unpaired Student t test. All pharmacokinetic and
statistical analyses were conducted using Drug and Statistics
Software version 2.0 (Mathematical Pharmacology Professional
Committee of China, Shanghai, People’s Republic of China).14
To test the bioequivalence of the test and reference formula-
tions, ANOVA for the crossover design was conducted on Cmax,
AUC0–t, and AUC0–1. The ratios of Cmax, AUC0–t, and AUC0–1 were
calculated using the F score. The probability of exceeding the limits
of acceptance for bioequivalence established by the US Food and
Drug Administration (80%–125%) was obtained using two 1-sided
t tests.15,16 The formulations were to be considered bioequivalent
if calculations of a 90% CIs for the ratio of the means of the
measures for the test and reference formulations fell within
bioequivalence limits, 80% to 125%, for ln-transformation of Cmax
AUC0–t, and AUC0–1, and if 2 1-sided t tests showed P o 0.05.15,16
All pharmacokinetic and statistical analyses were conducted
using Drug and Statistics Software version 2.0.14 Individual
pharmacokinetic values were calculated and then the meanscalculated. All analyses were performed using SPSS version 11.5
(IBM-SPSS Inc, Armonk, NY).Results
Subjects
A total of 22 subjects (mean [SD) age, 24.2 [2.3) years [range,
20–29 years]; weight, 62.6 [5.8) kg [range, 51–74 kg]; height, 172
[5.7) cm [range, 161–185 cm]) were enrolled in the study. All
subjects completed both periods, with no protocol violations. Vital
signs, physical examinations, ECGs, and clinical laboratory assess-
ments remained within normal limits for all subjects, with no
clinically meaningful differences between groups.
Method validation and stability testing
The method was shown to be suitable for the determination
of repaglinide in human plasma over the range of 0.306 to 30.6 ng/
mL (r Z 0.999). Using weighted least-squares regression, the
lower limit of quantitation was 0.306 ng/mL plasma. Accuracy
measured at 3 concentration levels was acceptable (varied from
85.42%–114.71%) and the relative SD values were all o3.50%.
Precision was likewise acceptable (between 1.66% and 8.23%).
Repaglinide and the internal standard nateglinide were stable in
plasma at room temperature for at least 24 hours, as well as for
30 days, at –801C after 3 freeze–thaw cycles. The analytic method
for repaglinide quantitation in plasma samples was validated and
applied to the bioequivalence study according to international
guidelines.
Repaglinide pharmacokinetics
Table I summarizes the mean [SD] pharmacokinetic parameters
of repaglinide after single-dose administration of 2 2-mg tablet
formulations in 22 healthy Chinese male volunteers. The mean
[SD] Cmax for repaglinide with the test formulation was 20.0 [5.1]
ng/mL and Tmax was 1.2 [0.7] hours. With the reference formula-
tion, the corresponding values were 18.7 [8.7] ng/mL and 1.5 [0.8]
hours, respectively. The mean [SD] t1/2 values with the test and
reference formulations were 1.0 [0.3] and 0.9 [0.3] hours, respec-
tively. With ANOVA, no period or sequence effects were observed
for any pharmacokinetic property. The mean plasma concen-
tration-time proﬁles of the 2 formulations after administration of
a single oral dose of repaglinide are shown in the Figure.
Table II shows the 90% CIs of the ratios (test/reference) for the
ln-transformed values of pharmacokinetic parameters, as well
as the probability of exceeding the limits of acceptance for
bioavailability and the power of the test in the 22 healthy Chinese
male volunteers. The results were shown to meet the predeter-
mined criteria for bioequivalence.
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Figure. Mean [SD] plasma drug concentrations over 6 h after single-dose administration of two 2-mg tablet formulations of repaglinide in 22 healthy Chinese male
volunteers.
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Repaglinide appeared to be well tolerated by all volunteers. No
adverse events were reported by volunteers or found on analysis
of vital signs or laboratory test results.Discussion
Our study assessed the bioequivalence of single dose of 2 tablet
formulations of repaglinide. There were no signiﬁcant differences
between formulations in pharmacokinetic properties in this small,
selected, fasting, healthy Chinese male volunteer population.
Although the branded repaglinide tablet formulation was already
marketed in China, published information regarding the pharma-
cokinetics of repaglinide and the bioequivalence of these formu-
lations in Chinese populations had never been reported. No
signiﬁcant differences were observed between the 2 oral formu-
lations in terms of pharmacokinetic parameters.
The peak plasma concentrations occurred 1.2 to 1.5 hours after
single-dose administration of 2 2-mg tablet formulations of repagli-
nide. Both formulations were apparently readily absorbed from the
gastrointestinal tract, and repaglinide was measurable at the ﬁrst
sampling time (at 0.25 hour). The mean plasma proﬁles and
bioavailability of the volunteers were similar between the 2 formu-
lations of repaglinide in this single-dose pharmacokinetic analysis.
In our study, no period or sequence effects for any pharmaco-
kinetic property were found using ANOVA in the healthy Chinese
male volunteers. The absence of a sequence effect in bothTable II
Comparison of 90% CIs for the ln-transformed ratios of pharmacokinetic parameters
of 2 2-mg tablet formulations of repaglinide in 22 healthy Chinese male volunteers;
the probability of exceeding the limits of acceptance for bioavailability and power.
Parameter Ratio,
test/reference
90% CI P for for exceeding the limits
of acceptance for
bioavailability
Power
o80% 4125%
Cmax 113.6 99.8–129.2 o0.001 o0.001 0.99
AUC0–t 105.6 93.4–119.5 o0.001 o0.001 0.99
AUC0–1 104.7 91.8–119.5 o0.001 o0.001 0.99parameters suggests that there was no carryover effect for these
22 subjects. These results indicate that a washout period of 7 days
was adequate for total elimination of the drug between the
2 administration periods.
There are several studies on the clinical pharmacokinetic
properties of repaglinide published in the literature. However,
most of them have been performed with Western volunteers.
Pharmacokinetic studies of repaglinide conducted with Asian races
have seldom been reported. In a study of pharmacokinetics of a
single-dose administration of 2-mg tablet formulations of repagli-
nide in healthy American volunteers (N ¼ 24), the pharmacoki-
netics of repaglinide were similar in healthy young adult and
elderly subjects. In the study, the AUC for repaglinide was 69.0
ngh/mL and Cmax was 47.9 ng/mL.7 The Tmax value was 0.8 hour,
and the t1/2 value was 1.0 hour. In another pharmacokinetics study
of a single-dose administration of 2-mg tablet formulations of
repaglinide carried out in Germans, the AUC for repaglinide was
36.03 nghour/mL and Cmax was 30.96 ng/mL.17 The Tmax value
was 0.8 hours. Thus, the repaglinide values of Cmax were higher
in whites than in our Chinese subjects and the values of Tmax were
much lower. However, drug was not administered with water
containing glucose and followed by administration of oral glucose
solution at speciﬁed intervals in the studies performed with
Western volunteers. Therefore, additional glucose solution in our
study may have resulted in the reduction of Cmax. However, the
prolonged Tmax and changed AUC may be attributed to the differ-
ence between Asians and whites.
Repaglinide is ﬁrst taken up from the blood to hepatocytes by
OATP1B1 and then metabolized in the liver mainly by CYP3A4 and
CYP2C8, which are genetically polymorphic enzymes. In 1 study in
China,12 the results showed that the polymorphism of SLCO1B1
(the encoding gene of the human OATP1B1) has signiﬁcant
inﬂuence on the pharmacokinetics of repaglinide. The SLCO1B1
variants were found to be relatively common in Chinese patients.
These frequencies were found to be similar to those observed in
healthy Chinese and Japanese individuals, but signiﬁcantly differ-
ent from whites and blacks.18 The CYP2C8 enzyme, which is
another genetic factor effect on the pharmacokinetics of repagli-
nide, has been mainly found in Africans (frequency, 0.04–0.18) and
whites (frequency, 0.10–0.23), but such frequencies have not been
observed in Asians.19 Some studies indicate that there are ethnic
differences in the expression levels of adult liver CYP3A mRNAs
between Japanese and whites, and that the mechanism regulating
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ethnic groups.20 In our study, the intersubject variation in the
pharmacokinetics of repaglinide was relatively large. The high
intersubject variation maybe explained by the natural interindi-
vidual variation in activity of OATP1B1, CYP3A4, and CYP2C8.
No subject withdrew from our study, and no adverse events were
found on analysis of vital signs or laboratory test results. However,
the study was limited by its short duration, its inclusion of only
healthy male volunteers under fasted conditions, and by its single-
dose, open-label design. The mean age of our healthy subjects was
24.2 years (range, 20–29 years) and, therefore, the study results
cannot be extrapolated to an older population. The results also
cannot be used to predict performance in patients in clinical practice.Conclusions
Our single-dose study found that the test and reference
formulations of repaglinide met the regulatory criteria for bio-
equivalence in these fasting, healthy Chinese male volunteers.
Both formulations appeared to be well tolerated.Acknowledgments
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